Project Grant R44HL160257

Award Date 5/1/22
Completion Date 4/30/26
Dollars Obligated $2.6M
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This $707,218 Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) will develop a new approach for secondary fetal screening using 0.55T MRI for high-risk pregnancies with poor acoustic windows that compromise diagnostic ultrasound. The project aims to: 1) assess the potential of 0.55T MRI as a secondary fetal screening modality, 2) compare 0.55T fetal MRI to standard 1.5T MRI, and 3)...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $295,895 to Ricovr Healthcare Inc. to develop a rapid, low-cost, point-of-care (POC) diagnostic platform for quantitative measurement of placental growth factor (PlGF) to predict and detect pre-eclampsia. The goal is to create an objective, affordable POC tool to improve the clinical diagnosis and monitoring of pre-eclampsia, which...
The National Institute of Child Health and Human Development (NICHD) awarded a $461,780 R21 project grant (CFDA 93.865: Child Health and Human Development Extramural Research) to The Regents of the University of California, San Francisco (UCSF) on August 1, 2023 to investigate the feasibility of a clinical-scale, anticoagulation-free artificial placenta device. The project aims to overcome key barriers to the clinical translation of artificial placenta technology, which is designed to simulate...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286) seeks to develop rapid, robust, and accurate methods for reconstructing coherent 3D fetal brain volumes from clinical 2D MRI scans. The goal is to integrate these reconstructed fetal brain volumes and automated brain biometrics into the clinical workflow to improve radiological...
This $516,556 Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB) under the "Discovery and Applied Research for Technological Innovations to Improve Human Health" (CFDA 93.286) program aims to develop and validate a novel, personalized flow modeling paradigm for assessing hemodynamics of the fetal aorta. The project, conducted by Worcester Polytechnic Institute (WPI), will focus on coarctation of the aorta, a common congenital heart...
This federal Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) aims to develop a non-invasive method for measuring fetal neurological activity using abdominal electroencephalography (EEG). The $451,850 award to Yale University will be used to first compare the new computerized abdominal fetal EEG (CAB-FEEG) technique to the existing invasive vaginal fetal EEG (V-FEEG) monitoring method....
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under CFDA 93.865 - Child Health and Human Development Extramural Research program provides $624,998 in funding to Giner Inc., a small business research and development firm, to develop a point-of-care testing (POCT) instrument for highly sensitive and near-real-time perinatal monitoring of oxytocin levels. The goal is to create an electrochemical assay and POCT device that can accurately measure...
This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program provides $408,400.00 to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop and assess a wearable magnetoencephalography (MEG) system for use in children with epilepsy. The key products and services to be delivered under this 2-year...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop an accurate and continuous monitoring platform for classifying apnea of prematurity (AOP) in premature newborns. The $371,021 award to Makani Science Inc., a minority-owned small business, will fund a two-phase effort to create a multimodal AOP monitoring system utilizing machine learning. During the initial R61 phase, the team...
This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $2,245,769 to Pascall Systems, Inc. to develop an integrated brain state monitoring system for personalized anesthesia decision support. The goal is to prevent postoperative delirium in elderly patients and those at risk for Alzheimer's or related dementias. The key products to be delivered include: Establishing technical feasibility for integrating the company's FDA-cleared wireless EEG...

A SCALABLE SUPERCONDUCTING DUAL-SHIELDED FETAL MAGNETOCARDIOGRAPHY SYSTEM - PROJECT SUMMARY THERE ARE 26,000 UNEXPLAINED FETAL DEATHS IN THE US AND OVER 4 MILLION WORLDWIDE ANNUALLY. FETAL CARDIAC ARRYTHMIA IS A SIGNIFICANT CAUSE OF FETAL DEMISE AND IS DIAGNOSED IN 1-3% PREGNANCIES. WHILE MOST OCCURRENCES ARE BENIGN, SERIOUS ARRHYTHMIA CAN LEAD TO LIFE-THREATENING COMPLICATIONS IF UNDIAGNOSED OR UNTREATED. ECHOCARDIOGRAPHY AND CARDIOTOCOGRAPHY HAVE BEEN WIDELY USED TO ASSESS FETAL CARDIAC FUNCTION; HOWEVER, THEIR USE HAS NOT REDUCED THE INCIDENCE OF FETAL SUDDEN DEATH. FETAL MAGNETOCARDIOGRAPHY (FMCG) RECORDS THE MAGNETIC FIELDS GENERATED BY THE ELECTRICAL ACTIVITY OF THE HEART, ENABLING DIRECT ASSESSMENT OF FETAL HEART ELECTROPHYSIOLOGY. HOWEVER, THE ONLY FDA-APPROVED FMCG SYSTEM USES EXPENSIVE SQUID SENSORS AND REQUIRES A DEDICATED MAGNETICALLY SHIELDED ROOM (MSR) TO ACHIEVE THE NECESSARY SENSITIVITY TO DETECT THE FETAL MAGNETIC SIGNAL ABOVE ENVIRONMENTAL MAGNETIC INTERFERENCE. THUS, THE PROHIBITIVE EXPENSE AND IMPRACTICALITY LIMITS THE USE OF A POTENTIALLY LIFE-SAVING DEVICE AND THERE REMAINS SIGNIFICANT NEED FOR A SENSITIVE DEVICE THAT IS AFFORDABLE AND ACCESSIBLE TO IMPROVE OUTCOMES FOR FETAL CARDIAC ARRHYTHMIAS. APPLIED PHYSICS SYSTEMS' (APS) SOLUTION IS AN INTEGRATED FMCG SYSTEM THAT USES THE MORE AFFORDABLE, OPTICALLY PUMPED MAGNETOMETER SENSORS (OPMS), WHICH ARE NOW AS SENSITIVE AS SQUID SENSORS, WITH AN INNOVATIVE SUPERCONDUCTING DUAL-SHIELD. A LABORATORY PROTOTYPE OF AN OPM-BASED FMCG WITH A PERSON-SIZED FERROMAGNETIC SHIELD HAS ALREADY BEEN DEVELOPED AND A HUMAN SUBJECT STUDY DEMONSTRATED FEASIBILITY OF AN OPM-BASED FMCG SYSTEM AS SENSITIVE AND ACCURATE AS SQUID-BASED FMCG, BUT AT A FRACTION OF THE COST. HOWEVER, THE SHIELD IN THE LABORATORY PROTOTYPE ALLOWED HIGHER NOISE IN THE FMCG RECORDINGS COMPARED TO SQUID IN AN MSR. THIS SHIELDING IS THE REMAINING TECHNICAL HURDLE TO REACH COMMERCIALIZATION. SUPERCONDUCTING SHIELDS HAVE SUPERIOR SHIELDING COMPARED TO FERROMAGNETIC SHIELDS AND APS HAS 40 YEARS OF SUCCESS IN COMMERCIALIZING SUPERCONDUCTING DUAL-SHIELDING IN ROCK MAGNETOMETER SYSTEMS. OUR PRELIMINARY DATA DEMONSTRATES PROOF OF CONCEPT OF IMPROVED OPM SENSITIVITY WITHIN SUCH A SHIELDING SYSTEM. THEREFORE, APS WILL BUILD UPON THESE STUDIES TO CREATE A SUPERCONDUCTING DUAL-SHIELD SYSTEM TO REDUCE ENVIRONMENTAL NOISE, THUS IMPROVING SIGNAL SENSITIVITY AND USABILITY OF THE SYSTEM THROUGH 3 AIMS. IN AIM 1, WE WILL SCALE UP OUR SUPERCONDUCTING DUAL-SHIELD SYSTEM TO BE PERSON-SIZED AND DESIGN THE OPM SENSOR ARRAY AND ITS ASSOCIATED SOFTWARE. WE WILL DEMONSTRATE THE SHIELDING PERFORMANCE OF OUR SYSTEM MATCHES OR EXCEED THAT OF A STANDARD MSR AND THERMAL PERFORMANCE OF THE SUPERCONDUCTING SYSTEM. IN AIM 2, WE WILL FULLY ASSEMBLE THE FMCG SYSTEM WITH A PATIENT CONVEYANCE SYSTEM AND CONFIRM IT MEETS ELECTRICAL SAFETY STANDARDS. IN AIM 3, WE WILL CONDUCT HUMAN SUBJECT STUDIES, FIRST IN NON- PREGNANT SUBJECTS TO CONFIRM SAFETY, THEN IN PREGNANT SUBJECTS TO CONFIRM SENSITIVITY AND ACCURACY OF OUR FMCG SYSTEM COMPARED TO THE FDA-APPROVED SQUID-BASED FMCG SYSTEM.

Posted 4/29/22, 12:00 AM